DYN Latest Press Releases

-- October 22, 2026 --

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- September 29, 2026 --

Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) Globe Newswire 4:05 PM

-- September 17, 2026 --

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- September 8, 2026 --

Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings Globe Newswire 7:51 AM

-- September 3, 2026 --

Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting Globe Newswire 7:30 AM

-- September 2, 2026 --

Dyne Therapeutics to Participate in Upcoming Investor Conferences Globe Newswire 7:30 AM

-- August 20, 2026 --

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- July 29, 2026 --

Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Globe Newswire 4:30 PM

-- July 28, 2026 --

Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD) Globe Newswire 7:30 AM

-- July 24, 2026 --

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- July 23, 2026 --

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares Globe Newswire 4:05 PM

-- July 21, 2026 --

Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock Globe Newswire 10:46 PM

Dyne Therapeutics Announces Proposed Public Offering of Common Stock Globe Newswire 4:46 PM

-- July 20, 2026 --

Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) Globe Newswire 7:30 AM

-- June 22, 2026 --

Dyne Therapeutics Appoints Barry Greene to Board of Directors Globe Newswire 4:10 PM

-- June 18, 2026 --

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- June 17, 2026 --

Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc. Globe Newswire 7:30 AM

-- June 3, 2026 --

Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1) Globe Newswire 7:30 AM

Market Data Delayed 15 Minutes